510(k)

K091820: CONTOUR USB BLOOD GLUCOSE METER, GLUCOSE TEST STRIPS; GLUCOFACTS DELUX DIABETES MANAGEMENT SYSTEM

FDA 510(k) · Bayer Healthcare · decided Aug 26, 2009

Key facts

510(k) number K091820
Device name CONTOUR USB BLOOD GLUCOSE METER, GLUCOSE TEST STRIPS; GLUCOFACTS DELUX DIABETES MANAGEMENT SYSTEM
Applicant Bayer Healthcare
Product code NBW
Subsequent product codes JQP, LFR
Date received Jun 18, 2009
Decision date Aug 26, 2009
Decision Substantially equivalent (SESE)
Submission type Special
Review panel Clinical Chemistry
Medical specialty Clinical Chemistry

At a glance

  • 100–999 MAUDE adverse event reports
  • None Recall events
  • 1–9 UDI device identifiers (GUDID)
  • None Predicate devices cited
  • 1–9 Later submissions citing this device
  • 100–999 510(k)s with this product code
  • No 510(k) summary on file
  • Yes 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications